Tema Cardiovascular and Metabolic ETF invests in companies addressing obesity and cardiometabolic diseases with a low fee.

Tema Obesity & Cardiometabolic ETF (NASDAQ:HRTS) is an exchange-traded fund (ETF) that invests in companies focused on developing solutions for obesity and cardiometabolic diseases. Launched in November 2023, HRTS tracks firms involved in weight-loss drugs, diabetes treatments, and other related areas. The fund offers exposure to this growing market with a relatively low expense ratio of 0.75%. It started trading around $26 per share and currently sits at $32, with over $61 million in assets under management.
GET YOUR GRAFA EDGE NOW
Sign up free to follow this company
We'll switch on a 30-day Edge trial as a welcome gift